Evotec SE
EVO- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001412558
No open-market purchases or sales by Evotec SE insiders were filed in the last 90 days; 34 institutions reported holding it in 13F filings for Q2 2026, worth $9.07M in total; no superinvestor holds it.
Other share classesEVOTF
13F holders, Q4 2022
Institutional positions in Evotec SE as of Dec 31, 2022. Investment managers with $100 million or more in US stocks report their long positions on Form 13F within 45 days after each quarter ends. How 13F works
- Institutional holders
- 22
- +1 vs. Q3 2022
- Shares held
- 2.60M
- −2.34M (−47.3%) vs. Q3 2022
- Total value
- $21.1M
- −$22.4M (−51.5%) vs. Q3 2022
- New holders
- 4
- 6 more added
- Sold out
- 3
- 6 more reduced
1 institution that held it in Q3 2022 haven't filed for Q4 2022 yet. Not filing isn't selling, so they aren't counted as sold out or in the changes above.
Compare with Q3 2022: new holders, sold out and not filed yet
Holders and value by quarter
Institutions reporting EVO on Form 13F each quarter since Q1 2021, and the total value they reported. Values are as of each quarter end, so they also move with the share price.
| Quarter | Holders | Value |
|---|---|---|
| Q2 2026 | 34 | $9.07M |
| Q1 2026 | 46 | $20.3M |
| Q4 2025 | 44 | $30.4M |
| Q3 2025 | 37 | $35.9M |
| Q2 2025 | 37 | $40.5M |
| Q1 2025 | 25 | $30.4M |
| Q4 2024 | 26 | $36.9M |
| Q3 2024 | 24 | $29.6M |
| Q2 2024 | 28 | $35.0M |
| Q1 2024 | 20 | $38.7M |
| Q4 2023 | 28 | $66.5M |
| Q3 2023 | 24 | $12.0M |
| Q2 2023 | 20 | $15.4M |
| Q1 2023 | 19 | $14.5M |
| Q4 2022 | 22 | $21.1M |
| Q3 2022 | 22 | $43.5M |
| Q2 2022 | 21 | $57.3M |
| Q1 2022 | 22 | $83.3M |
| Q4 2021 | 20 | $157.3M |
| Q3 2021 | 0 | $0 |
| Q2 2021 | 0 | $0 |
| Q1 2021 | 0 | $0 |
Institutions, Q4 2022
Shares, value and share of portfolio for each institution holding Evotec SE; share changes are against Q3 2022.
| Institution | Shares | Value | % of portfolio | Change in shares | Action |
|---|---|---|---|---|---|
| Artal Group S.A. | 1,149,425 | $9.30M | 0.54% | 00.0% | Unchanged |
| Federated Hermes, Inc. | 750,000 | $6.07M | 0.02% | 00.0% | Unchanged |
| Millennium Management LLC | 237,141 | $1.92M | 0.00% | −129,338−35.3% | Reduced |
| Zurcher Kantonalbank (Zurich Cantonalbank) | 222,771 | $1.80M | 0.01% | 00.0% | Unchanged |
| Jane Street Group, LLC | 71,419 | $583.1K | 0.00% | +7,154+11.1% | Added |
| Morgan Stanley | 46,499 | $376.2K | 0.00% | +1,623+3.6% | Added |
| Renaissance Technologies LLC | 31,509 | $255.0K | 0.00% | +17,810+130.0% | Added |
| Old Mission Capital LLC | 24,535 | $198.5K | 0.01% | +24,535 | New |
| Optiver Holding B.V. | 21,476 | $174.0K | 0.01% | +21,476 | New |
| Citadel Advisors LLC | 13,284 | $107.5K | 0.00% | +13,284 | New |
| Geode Capital Management, LLC | 13,238 | $107.0K | 0.00% | 00.0% | Unchanged |
| FMR LLC | 7,618 | $61.6K | 0.00% | +7,618 | New |
| BlackRock Inc. | 6,378 | $51.6K | 0.00% | −4,180−39.6% | Reduced |
| Bank of America Corp | 3,931 | $31.8K | 0.00% | −7,936−66.9% | Reduced |
| UBS Group AG | 3,336 | $27.0K | 0.00% | +450+15.6% | Added |
| US Bancorp | 428 | $3.46K | 0.00% | +36+9.2% | Added |
| Washington Trust Co | 421 | $3.41K | 0.00% | 00.0% | Unchanged |
| Signaturefd, LLC | 350 | $2.83K | 0.00% | −110−23.9% | Reduced |
| Lindbrook Capital, LLC | 72 | $582 | 0.00% | +20+38.5% | Added |
| Parallel Advisors, LLC | 70 | $566 | 0.00% | −146−67.6% | Reduced |
| Bell Investment Advisors, Inc | 22 | $178 | 0.00% | 00.0% | Unchanged |
| Tower Research Capital LLC (TRC) | 17 | $0 | 0.00% | −1,135−98.5% | Reduced |
| Artisan Partners Limited Partnership | 0 | $0 | 0.00% | −2,287,892−100.0% | Sold out |
| Quadrant Capital Group LLC | 0 | $0 | 0.00% | −1,682−100.0% | Sold out |
| Royal Bank of Canada | 0 | $0 | 0.00% | −1,584−100.0% | Sold out |
| Wipfli Financial Advisors LLC, | – | – | – | – | Not filed |